• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
73,524.26 -719.08
( -0.97%)
Global Indices
Nasdaq
51,098.17 -484.76
(-0.94%)
Dow Jones
7,440.28 -165.03
(-2.17%)
Hang Seng
63,697.20 -2,890.92
(-4.34%)
Nikkei 225
10,368.25 0.20
(0.00%)
Forex
USD-INR
95.73 0.01
(0.01%)
EUR-INR
111.21 0.07
(0.06%)
GBP-INR
128.58 -0.06
(-0.05%)
JPY-INR
0.60 0.00
(0.01%)

EQUITY - MARKET SCREENER

Samtel (India) Ltd
Industry :  Electronics - Components
BSE Code
ISIN Demat
Book Value()
500371
INE538C01017
2.7059233
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SAMTELTD
0
34.92
EPS(TTM)
Face Value()
Div & Yield %
0.08
10
0
 

abate as industries ltd
Welcure Drugs & Pharmaceuticals reports standalone net loss of Rs 49.86 crore in the March 2026 quarter
May 30,2026
Net loss of Welcure Drugs & Pharmaceuticals reported to Rs 49.86 crore in the quarter ended March 2026 as against net profit of Rs 2.54 crore during the previous quarter ended March 2025. There were no Sales reported in the quarter ended March 2026 as against Rs 21.21 crore during the previous quarter ended March 2025.

For the full year,net loss reported to Rs 5.49 crore in the year ended March 2026 as against net profit of Rs 2.17 crore during the previous year ended March 2025. Sales rose 1388.96% to Rs 365.54 crore in the year ended March 2026 as against Rs 24.55 crore during the previous year ended March 2025.

ParticularsQuarter EndedYear Ended
Mar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.
Sales021.21 -100 365.5424.55 1389
OPM %03.02 --1.903.58 -
PBDT-49.862.55 PL -5.472.79 PL
PBT-49.862.54 PL -5.492.78 PL
NP-49.862.54 PL -5.492.17 PL